Catalyst Pharmaceuticals (NASDAQ:CPRX) has an average broker rating of 1.5, which is interpreted as a Strong Buy, as rated by 4 equity analysts. Nonetheless, 3 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 1 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 2, which is also a Buy.
Catalyst Pharmaceuticals (NASDAQ:CPRX) : The most positive equity analysts on Catalyst Pharmaceuticals (NASDAQ:CPRX) expects the shares to touch $6, whereas, the least positive believes that the stock will trade at $1 in the short term. The company is covered by 4 Wall Street Brokerage Firms. The average price target for shares are $3.5 with an expected fluctuation of $2.38 from the mean.
For the current week, the company shares have a recommendation consensus of Buy.
Catalyst Pharmaceuticals (NASDAQ:CPRX): stock turned positive on Tuesday. Though the stock opened at $0.75, the bulls momentum made the stock top out at $0.785 level for the day. The stock recorded a low of $0.73 and closed the trading day at $0.75, in the green by 2.74%. The total traded volume for the day was 759,338. The stock had closed at $0.73 in the previous days trading.
In an insider trading activity, Denkhaus Donald A, director of Catalyst Pharmaceuticals, Inc. had purchased 50,000 shares on June 14, 2016 in a transaction. The price per share was $0.65 and the total amount of the disclosed transaction was $32,500.The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing. This information is based on open market transaction at the market prices.
Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. Firdapse is used for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). CPP-115 is used for the treatment of addiction and epilepsy. CPP-109 is used to treat addiction. The Company is conducting a Phase III trial to determine the safety and efficacy of Firdapse in the treatment of LEMS. CPP-115 has been granted Orphan Drug Designation by the food and drug administration (FDA) for the treatment of infantile spasms and Orphan Medicinal Product Designation in the European Union, for West syndrome (a form of infantile spasms).